Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Follow-Up Studies
Humans
India
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Male
Middle Aged
Neoplasm Metastasis
Prednisone
/ administration & dosage
Prognosis
Retrospective Studies
Rituximab
/ administration & dosage
Social Planning
Survival Rate
Tertiary Care Centers
Vincristine
/ administration & dosage
Diffuse large B-cell lymphoma
extranodal
non-Hodgkin's lymphoma
pattern
survival
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
Historique:
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
27
1
2022
Statut:
ppublish
Résumé
Extranodal (EN) involvement in diffuse large B-cell lymphoma (DLBCL) carries poor prognosis. Both the number and the specific sites of EN involvement are important in predicting prognosis. Given that the epidemiologic pattern of DLBCL in India is different from the rest of the world and such data correlations are scarce from developing countries, we aimed to find out if specific site and number of EN involvement could predict survival in DLBCL. Patients with DLBCL treated with combination chemotherapy plus rituximab were included. Site and number of EN involvement were noted. Univariate analysis for survival was performed for EN involvement or not, specific site of involvement, and number of EN involvement (0/1 vs. ≥2). Among a total of 177 patients, 92 (52%) patients had EN disease. When patients with 2 or more EN sites were compared against patients with 0 or 1 site, there was significant reduction in both progression-free survival (PFS) and overall survival (OS) (3-year OS of 55% vs. 79%, P = 0.001, 3-year PFS of 42% vs. 65%, P = 0.001). When specific EN sites were studied for correlation with survival, involvement of skin/soft tissue, and serosa were associated with significant reduction in 3-year OS (33% vs. 74%, P = 0.011, and 63% vs. 75%, P = 0.03, respectively) and 3-year PFS (25% vs. 62%, P < 0.001, and 46% vs. 62%, P = 0.01, respectively). Two or more EN sites in DLBCL predicted inferior survival. Serosal and skin/soft tissue involvement also predicted poor survival.
Identifiants
pubmed: 34528545
pii: JCanResTher_2021_17_4_938_298616
doi: 10.4103/jcrt.JCRT_428_19
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
938-942Déclaration de conflit d'intérêts
None